Shares of Profound Medical (NASDAQ:PROF – Get Free Report) were up 2% during trading on Friday . The company traded as high as $5.29 and last traded at $5.22. Approximately 60,266 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 145,421 shares. The stock had previously closed at $5.12.
Profound Medical Price Performance
The business’s 50-day moving average price is $4.89 and its 200 day moving average price is $5.34. The company has a quick ratio of 7.07, a current ratio of 8.53 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $157.23 million, a P/E ratio of -3.58 and a beta of 0.55.
Get Profound Medical alerts:
Profound Medical (NASDAQ:PROF – Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Profound Medical had a negative net margin of 343.97% and a negative return on equity of 89.74%. The firm had revenue of $2.21 million during the quarter, compared to the consensus estimate of $4.75 million. Analysts anticipate that Profound Medical will post -1.12 EPS for the current fiscal year.
Hedge Funds Weigh In On Profound Medical
A number of large investors have recently modified their holdings of the company. Thompson Davis & CO. Inc. boosted its position in shares of Profound Medical by 3.3% in the second quarter. Thompson Davis & CO. Inc. now owns 210,495 shares of the company’s stock valued at $1,242,000 after acquiring an additional 6,645 shares during the period. Raymond James Financial Inc. lifted its position in Profound Medical by 5.5% during the second quarter. Raymond James Financial Inc. now owns 941,879 shares of the company’s stock valued at $5,557,000 after purchasing an additional 49,000 shares during the last quarter. Ardsley Advisory Partners LP lifted its position in Profound Medical by 11.9% during the second quarter. Ardsley Advisory Partners LP now owns 330,000 shares of the company’s stock valued at $1,947,000 after purchasing an additional 35,000 shares during the last quarter. TD Waterhouse Canada Inc. lifted its position in Profound Medical by 36.3% during the second quarter. TD Waterhouse Canada Inc. now owns 56,073 shares of the company’s stock valued at $342,000 after purchasing an additional 14,920 shares during the last quarter. Finally, MMCAP International Inc. SPC lifted its position in Profound Medical by 2.1% during the second quarter. MMCAP International Inc. SPC now owns 490,859 shares of the company’s stock valued at $2,896,000 after purchasing an additional 10,000 shares during the last quarter. 47.86% of the stock is currently owned by institutional investors.
About Profound Medical
(Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Recommended Stories
Five stocks we like better than Profound Medical
What is the MACD Indicator and How to Use it in Your Trading
Pfizer is Locking in New Growth Through a New Acquisition
Why is the Ex-Dividend Date Significant to Investors?
Copper Giant Freeport Slumps but Analysts See 33% Upside
High Flyers: 3 Natural Gas Stocks for March 2022
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Profound Medical (NASDAQ:PROF) Stock Price Up 2% – Here’s What Happened
